Estimated Cancer Prevalence by Cancer Site and Gender, New York State Excl New York City, 2020
Source: New York State Cancer Registry
Site of Cancer | Diagnosed in Last 5 Years | Ever Diagnosed | ||||
---|---|---|---|---|---|---|
Males and Females | Males | Females | Males and Females | Males | Females | |
All Invasive Malignant Tumors | 252,100 | 125,200 | 126,900 | 712,200 | 331,800 | 380,400 |
Oral cavity and pharynx | 6,600 | 4,600 | 2,000 | 16,000 | 10,600 | 5,400 |
Esophagus | 1,400 | 1,100 | 300 | 2,600 | 2,000 | 600 |
Stomach | 2,800 | 1,600 | 1,200 | 5,800 | 3,300 | 2,500 |
Colorectal | 18,600 | 9,600 | 9,000 | 56,900 | 28,000 | 28,900 |
Liver / intrahepatic bile duct | 2,100 | 1,500 | 600 | 3,500 | 2,400 | 1,000 |
Pancreas | 3,200 | 1,700 | 1,600 | 4,800 | 2,400 | 2,400 |
Larynx | 1,700 | 1,300 | 400 | 4,600 | 3,600 | 1,000 |
Lung and bronchus | 20,800 | 8,900 | 11,900 | 34,400 | 14,400 | 20,100 |
Melanoma of the skin | 14,300 | 8,100 | 6,200 | 42,600 | 22,200 | 20,400 |
Female breast | 45,900 | 156,200 | ||||
Cervix uteri | 1,500 | 9,000 | ||||
Corpus uterus and NOS | 10,600 | 36,300 | ||||
Ovary | 2,900 | 10,200 | ||||
Prostate | 45,100 | 143,100 | ||||
Testis | 1,700 | 10,700 | ||||
Urinary bladder (incl. in situ) | 14,600 | 11,000 | 3,600 | 40,100 | 29,200 | 10,800 |
Kidney and renal pelvis | 10,500 | 6,800 | 3,700 | 28,300 | 17,600 | 10,700 |
Brain and other central nervous system | 1,900 | 1,100 | 900 | 7,600 | 3,900 | 3,600 |
Thyroid | 10,600 | 2,900 | 7,700 | 40,500 | 9,700 | 30,800 |
Hodgkin lymphoma | 1,700 | 900 | 800 | 9,800 | 5,000 | 4,800 |
Non-Hodgkin lymphomas | 11,900 | 6,300 | 5,600 | 33,900 | 17,800 | 16,200 |
Myeloma | 4,100 | 2,300 | 1,800 | 7,500 | 4,100 | 3,300 |
Leukemias | 8,300 | 4,900 | 3,400 | 23,200 | 13,200 | 9,900 |
Notes
- Estimated number of residents alive as of January 1, 2020, diagnosed with cancer within the last 5 years or anytime in the past, respectively.
- Numbers are rounded to the nearest 100.
- Refer to https://www.naaccr.org/wp-content/uploads/2020/01/CINA12-16.v5.sec1_.pdf for a detailed description of prevalence methodology.